PTGS2 and schwannoma: Interestingly, the treatment of NF2-null Schwann or schwannoma cells with a COX-2 inhibitor, celecoxib, dramatically inhibited cell growth in vitro and in vivo [114], which suggests that COX-2 is a potential therapeutic target in NF2-null tumors.